Research Paper Volume 16, Issue 12 pp 10489—10511
Identification of a signature of histone modifiers in kidney renal clear cell carcinoma
Figure 7. Prognostic analysis of HMs-based signature in the test set. (A) Expression of HMs of KIRC samples between high- and low-risk groups. (B) Kaplan-Meier survival analysis of KIRC samples between high- and low-risk groups. (C, D) Analysis of differences in survival status of KIRC samples between high- and low-risk groups. (E) Time-dependent ROC curve analysis of risk scores predicting 3- and 5-year OS in the KIRC samples.